Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-21T02:38:30.519Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy Comparison of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: Pooled Analysis of Placebo-Controlled Trials

Published online by Cambridge University Press:  07 November 2014

Jack M. Gorman ,
Andrew Korotzer  and
Guojin Su
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: Citalopram is a racemic selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of depression. Citalopram is a racemate and its serotonin reuptake inhibitory activity resides primarily in the single S-isomer, escitalopram, which is now being evaluated for its potential usefulness in the treatment of depression and other psychiatric disorders. Results from placebo-controlled studies that also included Citalopram as an active control have shown that escitalopram is effective in treating depression and associated symptoms of anxiety. However, none of these studies was powered sufficiently to detect differences between active treatment groups. The goal of the present analysis is to evaluate the efficacy of escitalopram compared with Citalopram in the treatment of major depressive disorder.

Method: Data were pooled from three similarly designed, randomized, double-blind, placebo-controlled trials of escitalopram (10–20 mg/day) and Citalopram (20–40 mg/day). Patients were male or female, ≥18 years of age, who met criteria for a major depressive episode with a Montgomery Asberg Depression Rating Scale (MADRS) score ≥22 at baseline. Efficacy measures included change from baseline in MADRS score and the Clinical Global Impression of Improvement (CGI-I) scale. Improvement in associated symptoms of anxiety was measured using the change from baseline in the MADRS inner tension item.

Results: Both escitalopram and Citalopram significantly improved depression and anxiety symptoms compared with placebo, and there were significantly more MADRS responders (defined as ≥50% improvement in MADRS scores at end point) in the escitalopram and Citalopram treatment groups. Escitalopram treatment was associated with statistically significant improvements in all efficacy measures relative to placebo after 1 week of treatment, whereas Citalopram treatment statistically separated from placebo at the end of week 4 (CGI-I and MADRS inner tension) or week 6 (MADRS). Escitalopram treatment also was statistically significantly superior to Citalopram treatment at a number of time points.

Conclusion: These data support the effectiveness of escitalopram and Citalopram in the treatment of major depressive disorder, and suggest escitalopram may have a faster onset and greater overall magnitude of effect than citalopram in improving symptoms of depression and anxiety in patients with major depressive disorder.

Type
Research Article
Information
CNS Spectrums , Volume 7 , Issue S1: The Biological and Clinical Significance of Single Isomers , April 2002 , pp. 40 - 44
Copyright
Copyright © Cambridge University Press 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Feighner, JP, Overø, K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry. 1999;60:824–830.CrossRefGoogle ScholarPubMed
2.Mendels, J, Kiev, A, Fabre, LF. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety. 1999;9:54–60.3.0.CO;2-T>CrossRefGoogle ScholarPubMed
3.Wade, AG, Lepola, U, Koponen, HJ, Pedersen, V, Pedersen, T. The effect of citalopram in panic disorder. Br J Psychiatry. 1997;170:549–553.CrossRefGoogle ScholarPubMed
4.Lepola, UM, Wade, AG, Leinonen, EV, et al.A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry. 1998;59:528–534.CrossRefGoogle ScholarPubMed
5.Montgomery, SA, Kasper, S, Stein, DJ, Ban Hedegaard, K, Lemming, O. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001;16:75–86.CrossRefGoogle ScholarPubMed
6.Wikander, I, Sundblad, C, Andersch, B, et al.Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 1998;18:390–398.CrossRefGoogle ScholarPubMed
7.Hyttel, J, Bogeso, KP, Perregaard, J, Sanchez, C. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm Gen Sect. 1992;88:157–160.CrossRefGoogle ScholarPubMed
8.Owens, MJ, Knight, DL, Nemeroff, CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001;50:345–350.CrossRefGoogle ScholarPubMed
9.Hutt, AJ, Tan, SC. Drug chirality and its clinical significance. Drugs. 1996;52 (suppl 5): 1–12.CrossRefGoogle ScholarPubMed
10.Tucker, GT. Chiral switches. Lancet. 2000;355:1085–1087.CrossRefGoogle ScholarPubMed
11.Burke, WJ, Gergel, I, Bose, A. Fixed dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002; in press.Google Scholar
12.Wade, AJ, Lemming, OM, Hedegaard, KB. Escitalopram 10 mg/day is effective and well tolerated in treating patients with depression in primary care. Int Clin Psychopharmacol. 2002; in press.Google Scholar
13.Montgomery, SA, Loft, H, Sanchez, C, Reines, EH, Papp, M. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol. 2001;88:282–286.CrossRefGoogle ScholarPubMed
14.Keller, MB. Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. J Clin Psychiatry. 2000;61:896–908.CrossRefGoogle ScholarPubMed
15.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
16.Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.CrossRefGoogle ScholarPubMed
17.Guy, W. NCDEU Assessment Manual for Psychopharmacology. 3rd ed. Rockville, MD: National Institute for Mental Health; 1976.Google Scholar
18.Thase, ME, Entsuah, AR, Rudolph, RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234–241.CrossRefGoogle ScholarPubMed
19.Beasley, CM, Dornseif, BE, Bosomworth, JC, et al.Fluoxetine and suicide: a metaanalysis of controlled trials of treatment for depression. BMJ. 1991;303:685–692.CrossRefGoogle ScholarPubMed
20.DeRubeis, RJ, Gelfand, LA, Tang, TZ, Simons, AD. Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry. 1999;156:1007–1013.CrossRefGoogle ScholarPubMed
21.Stahl, SM, Nierenberg, AA, Gorman, JM. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry. 2001;62 (suppl 4):17–23.Google ScholarPubMed
22.Stahl, SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry. 2000;48:894–901.CrossRefGoogle ScholarPubMed
23.Leon, AC, Blier, P, Culpepper, L, et al.An ideal trial to test differential onset of antidepressant effect. J Clin Psychiatry. 2001;62(suppl 4):34–36.Google ScholarPubMed